Pfizer and Allogene Agree to Collaborate on Developing Donor-derived CAR T-cell Therapies – Immuno-Oncology News
Immuno-Oncology News |
Pfizer and Allogene Agree to Collaborate on Developing Donor-derived CAR T-cell Therapies
Immuno-Oncology News Pfizer and Allogene Therapeutics have entered into a contribution agreement for Pfizer’s portfolio of assets related to donor-derived chimeric antigen receptor T-cell (CAR T) therapy, a kind of cell therapy directed at blood cancers and solid tumors … Allogene Therapeutics Completes Agreement for Pfizer’s Allogeneic CAR T Immuno-oncology PortfolioDigital Journal |
Business Wire (press release) |
Pfizer and Allogene Agree to Collaborate on Developing Donor-derived CAR T-cell Therapies
Immuno-Oncology News Pfizer and Allogene Therapeutics have entered into a contribution agreement for Pfizer’s portfolio of assets related to donor-derived chimeric antigen receptor T-cell (CAR T) therapy, a kind of cell therapy directed at blood cancers and solid tumors … Allogene Therapeutics Completes Agreement for Pfizer’s Allogeneic CAR T Immuno-oncology PortfolioBusiness Wire (press release) |
Phys.Org |
It’s all about the (stem cell) neighborhood
Phys.Org Stems cells in adult tissues live in very specific locations called stem cell niches. These niches provide a specialised, ideal neighbourhood for stem cells. The stem cells in the niche are undifferentiated, meaning they have not yet changed into … It’s all about the (stem cell) neighborhood — ScienceDailyScience Daily Are we on the brink of a stem cell revolution? – The TelegraphTelegraph.co.uk Even after FDA warnings, stem cell clinics still turning hope into hypeAtlanta Journal Constitution BioNews –Belarus News (BelTA) all 27 news articles » |